EI
STLN

EAM Investors’s Starling Oncology STLN Stock Holding History

EAM Investors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
+188,467
New +$792K 0.09% 224
2026
Q1 		– Sell
-182,509
Closed -$650K – 374
2025
Q4 		$650K Hold
182,509
– – 0.07% 244
2025
Q3 		$637K Sell
182,509
-13,328
-7% -$45.7K 0.07% 239
2025
Q2 		$401K Buy
+195,837
New +$490K 0.06% 218

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM Investors's STLN Position: Q2 2026 in Review

EAM Investors opened a new position in Starling Oncology (STLN) in Q2 2026: 188,467 shares worth $1.02M. The stake represents 0.09% of the portfolio and ranks #224 among its holdings. This is a return to the name: EAM Investors previously reported a position in STLN as recently as Q4 2025.

EAM Investors first reported a position in STLN in Q2 2025 and has held it in 4 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • EAM Investors held 188,467 shares of Starling Oncology worth $1.02M as of Q2 2026.
  • Starling Oncology was a new EAM Investors position in Q2 2026.
  • Starling Oncology made up 0.09% of EAM Investors's portfolio in Q2 2026, its #224 holding.
  • EAM Investors first reported a position in Starling Oncology in Q2 2025 and has held it in 4 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.